Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.218
-0.012 (-0.97%)
At close: Nov 4, 2024, 4:00 PM
1.200
-0.018 (-1.49%)
After-hours: Nov 4, 2024, 4:40 PM EST
Dermata Therapeutics Employees
Dermata Therapeutics had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,227,069
Market Cap
1.84M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | 0 | - |
Dec 31, 2022 | 8 | 0 | - |
Dec 31, 2021 | 8 | 1 | 14.29% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Avinger | 72 |
iCoreConnect | 70 |
Applied DNA Sciences | 55 |
FOXO Technologies | 29 |
Helius Medical Technologies | 22 |
Bluejay Diagnostics | 10 |
Tivic Health Systems | 9 |
ZyVersa Therapeutics | 7 |
DRMA News
- 27 days ago - Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 - Accesswire
- 6 weeks ago - Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire
- 7 weeks ago - Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - Accesswire
- 3 months ago - Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Accesswire
- 3 months ago - Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - Accesswire
- 6 months ago - Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Accesswire
- 6 months ago - Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - Accesswire